What is the primary use of Neo-synephrine in ocular therapy?

Neo-synephrine, whose active ingredient is phenylephrine, is primarily utilized in ocular therapy to induce mydriasis, which is the dilation of the pupil. This effect occurs because phenylephrine acts as a selective alpha-1 adrenergic agonist, leading to the contraction of the dilator muscle of the iris.

This property makes it particularly useful in various diagnostic and therapeutic procedures where a larger view of the interior of the eye is necessary, such as during a fundoscopic examination, wherein healthcare professionals need to assess the retina and optic nerve. The dilation allows better illumination and visibility, facilitating a more thorough examination by optimally expanding the field of view.

In contrast, constricting the pupil is not an intended use for Neo-synephrine; rather, medications like pilocarpine are used for that purpose. Similarly, while decreasing intraocular pressure is crucial for conditions like glaucoma, Neo-synephrine does not primarily serve this function, as other agents are designated for that role. Lastly, Neo-synephrine does not play a role in treating infections, a function typically reserved for antibiotic or antiviral medications specifically targeted to the pathogen causing the infection.